Come si colloca il rapporto MESO di PB rispetto ai suoi colleghi?

MESO ha un buon valore in base al suo rapporto Price-To-Book ( 2.5 x) rispetto alla media dei peer ( 3.1 x).

Come si colloca il MESO's PB Ratio rispetto ad altre aziende del US Biotechs settore?

MESO è costoso in base al suo rapporto Price-To-Book ( 2.5 x) rispetto alla media del settore US Biotechs ( 1.8 x).

Qual è il MESO PB Ratio rispetto al suo Fair PB Ratio? Si tratta del PB Ratio atteso, tenendo conto delle previsioni di crescita degli utili, dei margini di profitto e di altri fattori di rischio della società.

Dati insufficienti per calcolare il Fair Ratio di MESO Price-To-Book per l'analisi di valutazione.

Qual è il prezzo equo di MESO se si considerano i suoi flussi di cassa futuri? Per questa stima utilizziamo un modello di Discounted Cash Flow.

MESO ( $10.82 ) viene scambiato al di sotto della nostra stima del [[fair value]] ( $167.14 )

Qual è la previsione a 12 mesi degli analisti e abbiamo una qualche fiducia statistica nell'obiettivo di prezzo del consenso?

Dati insufficienti per mostrare la previsione dei prezzi.

Mesoblast (Nasdaq:MESO) - Prezzo delle azioni, notizie e analisi

MESO Panoramica delle azioni

Mesoblast Limited è impegnata nello sviluppo di prodotti di medicina rigenerativa in Australia, Stati Uniti, Singapore e Svizzera. Maggiori dettagli

MESO analisi fondamentale
Punteggio fiocco di neve
Valutazione	3/6
Crescita futura	5/6
Prestazioni passate	0/6
Salute finanziaria	4/6
Dividendi	0/6

Premi

Negoziato a 93.5% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 61.47% all'anno

Analisi del rischio

Gli azionisti sono stati diluiti nell'ultimo anno

Prezzo delle azioni volatile negli ultimi 3 mesi

Mesoblast Limited Concorrenti

Gracell Biotechnologies

NasdaqGS:GRCL

US$990.8m

Arcus Biosciences

NYSE:RCUS

US$1.3b

CareDx

NasdaqGM:CDNA

US$1.2b

Prothena

NasdaqGS:PRTA

US$756.0m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Mesoblast
Prezzi storici delle azioni
Prezzo attuale dell'azione	AU$10.82
Massimo di 52 settimane	AU$12.18
Minimo di 52 settimane	AU$1.61
Beta	2.34
1Variazione di 1 mese	12.12%
Variazione a 3 mesi	68.27%
Variazione di 1 anno	303.73%
3Variazione a 3 anni	-15.20%
Variazione a 5 anni	-14.80%
Variazione dall'IPO	32.73%

Notizie e aggiornamenti recenti

Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential

Sep 30

Mesoblast: Rolling The Dice On Cellular Medicines

Jul 22

Recent updates

Mesoblast's remestemcel-L reduces mortality by 46% in patients under age 65 with COVID-19 ARDS

Apr 30

Mesoblast issues FQ2 operational and financial update

Jan 29

Mesoblast's rexlemestrocel-l reduces heart attacks, strokes

Jan 11

Mesoblast: The Future Looks Bleak

Dec 24

Mesoblast fails to meet primary endpoint of reduction in recurrent non-fatal heart failure events

Dec 15

Mesoblast cell therapy Fast Track'd for COVID-19-related acute respiratory distress syndrome; shares up 14%

Dec 02

Mesoblast EPS beats by $0.22, misses on revenue

Nov 19

Rendimenti per gli azionisti

	MESO	US Biotechs	US Mercato
7D	-7.6%	-7.5%	-1.2%
1Y	303.7%	14.1%	30.4%

Ritorno vs Industria: MESO ha superato il US Biotechs che ha restituito 14.1 % nell'ultimo anno.

Rendimento vs Mercato: MESO ha superato il mercato US che ha restituito 30.4 % nell'ultimo anno.

Volatilità dei prezzi

Is MESO's price volatile compared to industry and market?
MESO volatility
MESO Average Weekly Movement	11.1%
Biotechs Industry Average Movement	9.7%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	3.1%

Prezzo delle azioni stabile: Il prezzo delle azioni di MESO è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale di MESO è diminuita da 17% a 11% nell'ultimo anno, ma è comunque superiore al 75% delle azioni US.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2004	73	Silviu Itescu	www.mesoblast.com

Mesoblast Limited è impegnata nello sviluppo di prodotti di medicina rigenerativa in Australia, Stati Uniti, Singapore e Svizzera. La sua piattaforma tecnologica proprietaria di medicina rigenerativa si basa su cellule specializzate note come cellule di lignaggio mesenchimale. L'azienda offre Remestemcel-L, in fase di sperimentazione clinica di Fase III per il trattamento di malattie infiammatorie sistemiche, tra cui la malattia acuta da trapianto contro l'ospite refrattaria agli steroidi e la malattia infiammatoria intestinale refrattaria ai farmaci biologici, nonché il morbo di Crohn; e Remestemcel-L, in fase di sperimentazione clinica di Fase III per il trattamento dell'insufficienza cardiaca cronica e della lombalgia cronica dovuta alla malattia degenerativa del disco.

Mesoblast Limited Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Mesoblast con la sua capitalizzazione di mercato?
MESO statistiche fondamentali
Capitalizzazione di mercato	US$1.20b
Guadagni(TTM)	-US$87.96m
Ricavi(TTM)	US$5.90m

202.7x

Rapporto P/S

-13.6x

Rapporto P/E

MESO è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
MESO Conto economico (TTM)
Ricavi	US$5.90m
Costo del fatturato	US$41.07m
Profitto lordo	-US$35.17m
Altre spese	US$52.79m
Guadagni	-US$87.96m

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-0.077
Margine lordo	-595.87%
Margine di profitto netto	-1,490.27%
Rapporto debito/patrimonio netto	23.8%

Come si è comportato MESO nel lungo periodo?

Vedi performance storica e confronto

MESO Panoramica delle azioni

Premi

Analisi del rischio

Mesoblast Limited Concorrenti

NasdaqGS:GRCL

US$990.8m

NYSE:RCUS

US$1.3b

NasdaqGM:CDNA

US$1.2b

NasdaqGS:PRTA

US$756.0m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Mesoblast Limited, Annual General Meeting, Nov 15, 2024

Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential

Mesoblast Limited Announces the United States Food and Drug Administration Has Accepted Its Biologics License Application (Bla) Resubmission for Ryoncil®

Mesoblast Limited Announces Patient Enrollment Commences in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain

Mesoblast: Rolling The Dice On Cellular Medicines

Mesoblast Limited Resources Biologics Licence Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil in the Treatment of Children with SR-aGVHD

Recent updates

Mesoblast Limited, Annual General Meeting, Nov 15, 2024

Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential

Mesoblast Limited Announces the United States Food and Drug Administration Has Accepted Its Biologics License Application (Bla) Resubmission for Ryoncil®

Mesoblast Limited Announces Patient Enrollment Commences in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain

Mesoblast: Rolling The Dice On Cellular Medicines

Mesoblast Limited Resources Biologics Licence Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil in the Treatment of Children with SR-aGVHD

Mesoblast to File Biologics License Application for Ryoncil FDA Approval Next Week

Mesoblast Limited: Back From The Dead

United States Food & Drug Administration Notifies Mesoblast Limited of Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease

Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 0.93 million.

Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 97.041224 million.

Mesoblast Limited Announces United States Food & Drug Administration Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with A Left Ventricular Assist Device

United States Food & Drug Administration Grants Mesoblast Rare Pediatric Disease Designation for Revascor®? (Rexlemestrocel-L) in Children with Congenital Heart Disease

Mesoblast Limited, Annual General Meeting, Nov 28, 2023

Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee

Mesoblast Limited Provides an Update on the Path to Approval for Its Lead-Product Candidate Remestemcel-L in the Treatment of Pediatric and Adult Steroid-Refractory Acute Graft Versus Host Disease

Mesoblast Limited Receives Complete Response from U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children

Mesoblast Limited Appoints Dr. Philip R. Krause, Member of the Board of Directors, to Formal Strategic Advisory Role

Remestemcel-L Clinical and Potency Studies Presented At Premier Meeting of Transplantation Research and Therapy

Mesoblast Limited Announces FDA Grants Regenerative Medicine Advanced Therapy Designation for Rexlemestrocel-L in Chronic Low Back Pain

Mesoblast Limited Resubmits Biologic License Application to FDA for Remestemcel-L in Children With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD)

Mesoblast Limited Announces Top-Line Long-Term Survival Results for Remestemcel-L from its Pivotal Phase 3 Trial (GVHD-001) in Children with Steroid-Refractory Acute Graft-Versus-Host Disease

Mesoblast Limited, Annual General Meeting, Nov 23, 2022

Mesoblast Limited Submits New Information to FDA File in Response to Items in the CRL to the Remestemcel-L BLA for SR-aGVHD

Mesoblast GAAP EPS of -$0.14, revenue of $10.21M

Mesoblast Limited Announces Board Changes

Mesoblast Limited Announces Single Intervention with Rexlemestrocel-L Improves Left Ventricular Ejection Fraction At 12 Months, Preceding Long-Term Reduction in Major Adverse Cardiovascular Events

Mesoblast Limited Provides Litigation Update

Mesoblast Limited Provides Update on Survival Outcomes in Covid-19 ARDS Patients Treated with Remestemcel-L

Mesoblast Limited Announces Class Action Proceeding in the Federal Court of Australia

Mesoblast Limited Announces Executive Changes

Donal O'Dwyer Retires from the Board of Mesoblast Limited

Mesoblast Limited Announces Positive Results from an Interim Analysis of the First Patient Cohort in the Randomized, Controlled Study of Remestemcel-L by Direct Endoscopic Delivery to Areas of Inflammation in Patients with Medically Refractory Ulcerative Colitis or Crohn's Colitis

Mesoblast Limited Appoints Eric Rose as Chief Medical Officer

Mesoblast Limited Announces 36-Month Results of Phase 3 Trial in Chronic Low Back Pain

Mesoblast Provides Update Following Meeting with FDA’s OTAT on Remestemcel-L for Children with Acute Graft Versus Host Disease

Mesoblast Limited Receives Feedback from the US Food & Drug Administration’S Office of Tissues and Advanced Therapies on the Phase 3 Program of Rexlemestrocel-L

Mesoblast Limited announced that it expects to receive $90 million in funding from Oaktree Capital Management, L.P.

Mesoblast Presents Respiratory Function Results of COVID-19 ARDS Trial at Pulmonary Disease Conference

Mesoblast Limited Provides Update on Program for Chronic Low Back Pain Due to Degenerative Disc Disease

Mesoblast Limited Improves Outcomes in Inflammatory Lung Disease with Remestemcel-L Published in Respiratory Research Journal

Mesoblast Limited Announces the 60 Day Results from the Randomized Controlled Trial of remestemcel-L in 222 Ventilator-Dependent COVID-19 Patients with Moderate/Severe Acute Respiratory Distress Syndrome (ARDS) Which Had Been Halted After the Third Interim Analysis

Mesoblast's remestemcel-L reduces mortality by 46% in patients under age 65 with COVID-19 ARDS

Mesoblast Limited announced that it expects to receive AUD 138.251367 million in funding

Mesoblast Limited Announces Positive Outcomes of First Children Treated with Remestemcel-L for Multisystem Inflammatory Syndrome (MIS-C) and Heart Failure Post-Covid-19 Published in Pediatrics

Mesoblast Limited Announces Results from the Phase 3 Randomized Controlled Trial of Its Allogeneic Mesenchymal Precursor Cell Therapy

Mesoblast issues FQ2 operational and financial update

Mesoblast Limited Presents Heart Failure Phase 3 Trial Results At Investor Healthcare Conference

Mesoblast Limited Announces Additional Results from the Landmark Dream-Hf Randomized Controlled Phase 3 Trial in 537 Treated Patients with Chronic Heart Failure with Reduced Left Ventricular Ejection Fraction (HFrEF) Who Received Rexlemestrocel-L (REVASCOR) or Control Sham

Mesoblast's rexlemestrocel-l reduces heart attacks, strokes

Mesoblast: The Future Looks Bleak

Mesoblast Limited Announces Update on Covid-19 ARDS Trial

Mesoblast Provides Topline Results From Phase 3 Trial of Rexlemestrocel-L for Advanced Chronic Heart Failure

Mesoblast fails to meet primary endpoint of reduction in recurrent non-fatal heart failure events

Mesoblast Limited Announces United States Food and Drug Administration Granted Fast Track Designation for Remestemcel-L in the Treatment of Acute Respiratory Distress Syndrome Due to Covid-19 Infection

Mesoblast Limited Announces FDA Grants Fast Track Designation for Remestemcel-L in the Treatment of Acute Respiratory Distress Syndrome Due to COVID-19

Mesoblast cell therapy Fast Track'd for COVID-19-related acute respiratory distress syndrome; shares up 14%

Mesoblast Limited announced that it expects to receive $25 million in funding from Novartis AG

Mesoblast Limited Enters into an Exclusive Worldwide License and Collaboration Agreement with Novartis for the Development, Manufacture and Commercialization of Remestemcel-L